Mohamed Gouda, MD, PhD

Peer-Reviewed Articles

1. Borea R, Saldanha EF, Maheswaran S, Nicolo E, Singhal S, Pontolillo L, de Miguel Perez D, Venetis K, Dipasquale A, Ghazali N, Pisapia P, Franco AO, Gouda MA, Reduzzi C. Cancer in a drop: Advances in liquid biopsy in 2024. Crit Rev Oncol Hematol 213:104776, 2025. e-Pub 2025. PMID: 40447209.
2. Gouda MA, Janku F, Yuan Y, Drusbosky LM, Chen AP, Zheng X, Patel K, Hamilton SR, Routbort M, Tricoli JV, Williams PM, Iafrate AJ, Sklar J, Coffey B, Little RF, Arteaga CL, O'Dwyer PJ, Flaherty KT, Harris LN, Meric-Bernstam F. Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131). Clin Cancer Res, 2025. e-Pub 2025. PMID: 40388547.
3. Gouda MA, Voss MH, Tawbi H, Gordon M, Tykodi SS, Lam ET, Vaishampayan U, Tannir NM, Chaves J, Nikolinakos P, Fan A, Lee R, McDermott D, Shapiro GI, Gandhi L, Bhatia S, Katragadda V, Meric-Bernstam F. A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. ESMO Open 10(5):104536, 2025. e-Pub 2025. PMID: 40359708.
4. Dumbrava EE, Olson D, Gouda MA, George MA, Saibil S, Apostolopoulou M, Bishop M, Gavriliuc MN, Kennon AM, Weiss JD, Ayers C, Moss K, Helsen CW, Bader AG, Adib D, Schlechter BL. Autologous T Cell Antigen Coupler (TAC) Targeting HER2 (TAC01-HER2) in Advanced or Metastatic Solid Tumors. e-Pub 2025.
5. Gouda MA, Voss M, Tawbi H, Gordon M, Tykodi S, Lam E, Vaishampayan U, Tannir NM, Chaves J, Nikolinakos P, Fan A, Lee R, McDermott D, Shapiro G, Gandhi L, Bhatia S, Muigai L, Jenkins Y, Meric-Bernstam AF. A Phase 1/2 Study of the Safety and Efficacy of Telaglenastat (CB-839) in Combination with Nivolumab in Patients with Metastatic Melanoma, Renal Cell Carcinoma, and Non-Small Cell Lung Cancer. ESMO Open. e-Pub 2025.
6. Derbala MH, Hajjar J, Stephen B, Gurses SA, Kwiatkowski E, Budde P, Zucht HD, Brautigam M, Lindermann AS, Abhari BA, Gouda MA, Castillo L, Zarifa A, How JA, Rodriguez E, Moyers JT, Hong DS, Fu S, Meric-Bernstam F, Naing A. Autoantibody profiling to predict response to anti-PD-1 therapy in rare tumors. e-Pub 2025.
7. Gouda MA, Lin HY, Kang L, Le H, Dumbrava EE, Fu S, Karp DD, Tsimberidou AM, Naing A, Piha-Paul SA, Pohlmann PR, Rodon J, Yap TA, Meric-Bernstam F, Hong DS. Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors. e-Pub 2025.
8. Xavier CB, Gouda MA, Tsimberidou AM. Prolonged Response to Dual Immune Checkpoint Blockade in Patients with Advanced Solid Tumors: A Case Series. e-Pub 2025.
9. Borea R, Saldanha E, Maheswaran S, Nicolo E, Singhal S, Pontolillo L, de Miguel Perez D, Venetis K, Dipasquale A, Ghazali N, Pisapia P, Franco AO, Gouda MA, Reduzzi C, on behalf of the International Society of Liquid Biopsy. Cancer in a Drop: 2024 Advances in Liquid Biopsy. e-Pub 2025.
10. Gouda MA, Ahmed J, Nelson BE, Nardo M, Roszik J, Cabanillas ME, Hu MI, Busaidy NL, Sherman SI, Dadu R, Naing A, Karp DD, Rodon A, Hong DS, Elamin YY, Blumenschein GR, Heymach J, Meric-Bernstam F, Subbiah V. Intrapatient comparative efficacy of selective RET inhibitors using growth modulation index in patients with RET aberrant cancers. e-Pub 2025.
11. Gouda MA, Ballesteros PA, Garrido-Laguna I, Rodon J. Efficacy assessment in phase I clinical trials: endpoints and challenges. Ann Oncol, 2025. e-Pub 2025. PMID: 40049448.
12. Gouda MA, Janku F, Yuan Y, Drusbosky L, Chen AP, Zheng X, Patel K, Hamilton SR, Routbort M, Williams PM, Iafrate J, Sklar J, Coffey B, Little RF, Arteaga CL, Abrams JS, O’Dwyer PJ, Flaherty KT, Harris LN, Meric-Bernstam F. Concordance between tumor tissue and plasma genotyping in NCI-MATCH trial (EAY131). Clinical Cancer Research. e-Pub 2025.
13. Pontolillo L, Gouda MA, Venetis K, Nicolo E, Reduzzi C. Cancer in a drop: Liquid biopsy highlights from San Antonio Breast Cancer Symposium (SABCS) 2024. The Journal of Liquid Biopsy 7, 2025. e-Pub 2025.
14. Alhalabi O, Gouda MA, Milton DR, Momin HA, Yilmaz B, Stephen B, Ejezie CL, Moyers JT, Gurses SA, How J, Fu S, Rodon J, Hong DS, Piha-Paul SA, Subbiah S, Dumbrava EE, Karp DD, Janku F, Meric-Bernstam F, Tannir NM, Naing A. A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma. Cancer Med 14(4), 2025. e-Pub 2025. PMID: 39945382.
15. Nardo M, Gouda MA, Reilley MJ, Biter AB, Lim J, Bean SA, Nguyen LM, Bhosale PR, Ager CR, Couillault CA, Piha-Paul SA, Fu S, Tsimberidou AM, Yap TA, Naing A, Rodon J, Subbiah V, Karp DD, Curran MA, Hong DS. Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial. J Immunother Precis Oncol 8(2):89-98, 2025. e-Pub 2025. PMID: 39959251.
16. Gouda MA, Wei Z, Rodon J, Davies MA, Janku F, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Liu R, Bota DA, Swiecicki PL, Buchschacher GL, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H. JCO Precis Oncol:e2400451, 2025. e-Pub 2025. PMID: 39913886.
17. Gouda MA, Zarifa A, Yang Y, Stephen B, Gurses SA, Sprenger A, Tian Y, Derbala MH, Glitza IC, Meric-Bernstam F, Patel SP. Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial. J Immunother Precis Oncol 8(1):82-88, 2025. e-Pub 2025. PMID: 39816915.
18. Gouda MA, Gouda MA, Pandey S, Chauhan NK, Shen T, Hu X, Li M, Huang S, Subbiah V, Wu J. Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model. Cancer Lett, 2025. e-Pub 2025. PMID: 39778760.
19. Gouda MA, Gonugunta A, Dumbrava EE, Yap TA, Rodon J, Piha-Paul SA, Pohlmann PR, Damodaran S, Murthy R, Valero V, Mouabbi J, Tripathy D, Sahin AA, Chen H, Meric-Bernstam F. Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer. Clin Cancer Res, 2025. e-Pub 2025. PMID: 39841861.
20. Reduzzi C, Nicolo E, Singhal S, Venetis K, Ortega-Franco A, de Miguel-Perez D, Dipasquale A, Gouda MA, Saldanha EF, Kasi PM, Jantus-Lewintre E, Fusco N, Malapelle U, Gandara DR, Rolfo C, Serrano MJ, Cristofanilli M. Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors. Crit Rev Oncol Hematol, 2024. e-Pub 2024. PMID: 39159706.
21. Gouda MA, Stephen B, Tian Y, Alshawa A, Onwugaje DOC, Albittar A, Yang Y, Zarifa A, Yilmaz B, Gurses S, Sprenger A, Derbala MH, Brink A, How JA, Moyers J, Piha-Paul SA, Hong DS, Meric-Bernstam F, Patel SP, Glitza IC. A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma. J Immunother Precis Oncol 7(4), 2024. e-Pub 2024. PMID: 39524469.
22. Polivka J, Gouda MA, Sharif M, Pesta M, Huang H, Treskova I, Woznica V, Windrichova J, Houfkova K, Kucera R, Fikrle T, Pivovarcikova K, Topolcan O, Janku F. Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early-Stage Malignant Melanoma. Cancer Med 13(19):e70313, 2024. e-Pub 2024. PMID: 39387479.
23. Gouda MA, Thein KZ, Hong DS. Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions. Cancers (Basel) 16(19):3395, 2024. e-Pub 2024. PMID: 39410015.
24. Subbiah V, Gouda MA, Ryll B, Burris HA, Kurzrock R. The evolving landscape of tissue-agnostic therapies in precision oncology. CA Cancer J Clin 74(5):433-452, 2024. e-Pub 2024. PMID: 38814103.
25. KhalafAllah MT, Gouda MA, Alfaar AS. In-Depth Analysis of Incidence and Survival of Lacrimal Gland Malignancies in the United States of America from 1995 to 2018. Ophthalmic Epidemiol 31(4), 2024. e-Pub 2024. PMID: 38011023.
26. Kairemo K, Macapinlac HA, Gouda MA, Subbiah V. Assessing the Effectiveness of Selective RET Inhibitors in RET-Positive Cancers through Fluorodeoxyglucose Uptake Analysis. Diagnostics (Basel) 14(17):1886, 2024. e-Pub 2024. PMID: 39272672.
27. Gouda MA, Shunyakova J, Naing A, Dumbrava E, Hong DS, Yuan Y, Yang P, Myers A, Liang Y, Peng J, Karp D, Tsimberidou AM, Rodon J, Yap TA, Piha-Paul SA, Meric-Bernstam F, Fu S. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. ESMO Open 9(6):103486, 2024. e-Pub 2024. PMID: 38914452.
28. Kairemo K, Gouda MA, Chuang HH, Macapinlac HA, Subbiah V. Deciphering Tumor Response: The Role of Fluoro-18-d-Glucose Uptake in Evaluating Targeted Therapies with Tyrosine Kinase Inhibitors. J Clin Med 13(11):3269, 2024. e-Pub 2024. PMID: 38892979.
29. Subbiah V, Gouda MA, Iorgulescu JB, Dadu R, Patel K, Sherman S, Cabanillas M, Hu M, Castellanos LE, Amini B, Meric-Bernstam F, Shen T, Wu J. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ Precis Oncol 8(1):62, 2024. e-Pub 2024. PMID: 38438731.
30. Gouda MA, Janku F, Wahida A, Buschhorn L, Schneeweiss A, Abdelkarim N, de Miguel Perez D, Del Re M, Russo A, Curigliano G, Rolfo C, Subbiah V. Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST). Ann Oncol 35(3), 2024. e-Pub 2024. PMID: 38145866.
31. Ahluwalia MS, Khosla AA, Ozair A, Gouda MA, Subbiah V. Impact of tissue-agnostic approvals on management of primary brain tumors. Trends Cancer 10(3):256-274, 2024. e-Pub 2024. PMID: 38245379.
32. Allam AR, Elsayed MA, Daghash IT, Abdelaziz AM, Mostafa OM, Sabra HK, Eldaboush AM, Ahmed NMB, Elweza RT, Adwy ES, Hammad AE, Kabbash IA, Allam AH, Bahbah AA, Ewis MI, Shawqi MM, Behery MB, El-Said YM, Radwan AE, KhallafAllah MT, Aboshady OA, Gouda MA. Colonoscopy screening for colorectal cancer in Egypt: a nationwide cross-sectional study. BMC Cancer 24(1), 2024. e-Pub 2024. PMID: 38273265.
33. Shawqi MM, El-Said YM, Behery MB, Abdelaziz A, Ibrahem ES, ElBoraie A, Khattab MA, Ghattas AS, Naeem A, Madany M, Elboraay T, Naguib MM, Allam AR, Allam AH, Bahbah AA, Ewis MI, Elsayed MA, Sherief L, KhallafAllah MT, Gouda MA, Aboshady OA. Knowledge, attitude, and practice of Egyptian medical students towards healthcare workers’ recommended vaccines: a nationwide cross-sectional survey”. Impact of tissue-agnostic approvals on management of primary brain tumors. BMC Med Educ 24(1):876, 2024. e-Pub 2024. PMID: 39143628.
34. Phadnis S, Wang X, Daw NC, Herzog CE, Subbiah IM, Zaky W, Gouda MA, Morani AC, Amini B, Harrison DJ, Piha-Paul SA, Meric-Bernstam F, Gorlick R, Schwartz CL, Subbiah V. Everolimus in combination with vandetanib in children, adolescents, and young adults: A Phase 1 study. ESMO Open 8(6):101609, 2023. e-Pub 2023. PMID: 37879233.
35. Nardo M, Gouda MA, Nelson BE, Barreto CMN, Slade JH, Poullard A, Zafereo M, Hu MI, Cabanillas ME, Subbiah V. Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers. Cell Rep Med 4(12):101332, 2023. e-Pub 2023. PMID: 38118420.
36. Denu RA, Moyers JT, Gouda MA, Conley AP, Lazar AJ, Subbiah V. The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications. Clin Cancer Res 29(22), 2023. e-Pub 2023. PMID: 37643131.
37. Blum J, Menta AK, Zhao X, Yang VB, Gouda MA, Subbiah V. Pearls and pitfalls of ChatGPT in medical oncology. Trends Cancer 9(10):788-790, 2023. e-Pub 2023. PMID: 37407364.
38. Gouda MA, Hu M, Cabanillas M, Wu J, Meric-Bernstam F, Subbiah V. Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors. Ann Oncol 34(10), 2023. e-Pub 2023. PMID: 37473872.
39. Gouda MA, Zarzour MA, Vaporciyan AA, Kairemo K, Chuang HH, Subbiah V. Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma. Oncoscience 10:44–53, 2023. e-Pub 2023. PMID: 37736255.
40. Shreenivas A, Janku F, Gouda MA, Chen HZ, George B, Kato S, Kurzrock R. ALK fusions in the pan-cancer setting: another tumor-agnostic target?. NPJ Precis Oncol 7(1), 2023. e-Pub 2023. PMID: 37773318.
41. Gouda MA, Janku F, Somaiah N, Hunt KK, Yedururi S, Subbiah V. Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery. Oncoscience 10:38-43, 2023. e-Pub 2023. PMID: 37736254.
42. Kairemo K, Gouda MA, Buschhorn L, Wahida A, Macapinlac HA, Anderson PM, Subbiah V. Sodium fluoride (Na18F) PET Response Criteria in Solid Tumors (NAFCIST): a framework for response assessment in bone tumors. ESMO Open 8(4), 2023. e-Pub 2023. PMID: 37517365.
43. Gouda MA, Nelson BE, Buschhorn L, Wahida A, Subbiah V. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications. Clin Cancer Res 29(15):2753-2760, 2023. e-Pub 2023. PMID: 37061987.
44. Gouda MA, Buschhorn L, Schneeweiss A, Wahida A, Subbiah V. N-of-1 Trials in Cancer Drug Development. Cancer Discov 13(6):1301-1309, 2023. e-Pub 2023. PMID: 37070849.
45. Gouda MA, Subbiah V. Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers. Ther Adv Med Oncol, 2023. e-Pub 2023. PMID: 37360768.
46. Gouda MA, Subbiah V. Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors. Am Soc Clin Oncol Educ Book, 2023. e-Pub 2023. PMID: 37159870.
47. Nelson BE, Reddy NK, Huse JT, Amini B, Nardo M, Gouda MA, Weathers SP, Subbiah V. Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma. NPJ Precis Oncol 7(1):47, 2023. e-Pub 2023. PMID: 37231247.
48. Gouda MA, Duose DY, Lapin M, Zalles S, Huang HJ, Xi Y, Zheng X, Aldesoky AI, Alhanafy AM, Shehata MA, Wang J, Kopetz S, Meric-Bernstam F, Wistuba II, Luthra R, Janku F. Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures. Oncologist 28(4):368-372, 2023. e-Pub 2023. PMID: 36200910.
49. Gouda MA, Subbiah V. Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy. ESMO Open 8(2):100788, 2023. e-Pub 2023. PMID: 36842301.
50. Johnson FM, Janku F, Gouda MA, Tran HT, Kawedia JD, Schmitz D, Streefkerk H, Lee JJ, Andersen CR, Deng D, Rawal S, Shah PS, El-Naggar AK, Johnson JM, Frederick MJ. Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer. Oncologist 27(12), 2022. e-Pub 2022. PMID: 36124629.
51. Gouda MA, Subbiah V. Strategies for Mitigating Antibody-Drug Conjugate Related Adverse Events for Precision Therapy. Cancer J 28(6):496-507, 2022. e-Pub 2022. PMID: 36383913.
52. Gouda MA, Huang HJ, Piha-Paul SA, Call SG, Karp DD, Fu S, Naing A, Subbiah V, Pant S, Dustin DJ, Tsimberidou AM, Hong DS, Rodon J, Meric-Bernstam F, Janku F. Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancer. JCO Precis Oncol 6:e2100512, 2022. e-Pub 2022. PMID: 35834760.
53. Gouda MA, Ong E, Huang HJ, McPhaul LW, Yoon S, Janku F, Gianoukakis AG. Ultrasensitive detection of BRAF V600E mutations in circulating tumor DNA of patients with metastatic thyroid cancer. Endocrine 76(2):491-494, 2022. e-Pub 2022. PMID: 35152349.
54. Lapin M, Huang HJ, Chagani S, Javle M, Shroff RT, Pant S, Gouda MA, Raina A, Madwani K, Holley VR, Call SG, Dustin DJ, Lanman RB, Meric-Bernstam F, Raymond VM, Kwong LN, Janku F. Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precis Oncol 6:e2100197, 2022. e-Pub 2022. PMID: 35171660.
55. Gouda MA, Polivka J, Huang HJ, Treskova I, Pivovarcikova K, Fikrle T, Woznica V, Dustin DJ, Call SG, Meric-Bernstam F, Pesta M, Janku F. Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma. ESMO Open 7(1):100357, 2022. e-Pub 2022. PMID: 34942440.
56. Gouda MA, Zidan HS, Marey AA, Gameal MG, Elmahrook RG, Saleh A, Nasr AA, Seifelnasr O, Radwan AE, Shahen A, Elgayar MM, Elabd AA, Mohamed KS, Hammad MF, Badr MM. Medical undergraduates' contributions to publication output of world's top universities in 2013. QJM 109(9):605-11, 2016. e-Pub 2016. PMID: 26970608.
57. Alkott MM, Gouda MA, KhalafAllah MT, Zahran MS, Kallaf MM, Zayed AM. Family Medicine in Egypt From Medical Students' Perspective: A Nationwide Survey. Teach Learn Med 27(3):264-73, 2015. e-Pub 2015. PMID: 26158328.
58. Gouda MA, Demestichas BR, Kuburich NA, Hollander PD, Mani SA, Subbiah V. Histological Transformation in Cancer as Mechanism of Resistance to Cancer Therapy.

Editorials

1. Pontolillo L, Gouda MA, Venetis K, Nicolo E, Reduzzi C. Cancer in a drop: Liquid biopsy highlights from San Antonio Breast Cancer Symposium (SABCS) 2024. J Liq Biopsy 7:100286, 2025. PMID: 40027228.
2. Karp DD, Osburn J, Gouda MA. Learning From Mistakes: Navigating Medical Errors in Oncology From Prevention to Management. J Immunother Precis Oncol 7(4):242-246, 2024. PMID: 39524468.
3. Saldanha EF, Nicolo E, Venetis K, de Miguel-Perez D, Ortega-Franco A, Dipasquale A, Gouda MA, Singhal S, Adigbli G, Reduzzi C. The role of liquid biopsy as a catalyst for sustained progress in precision oncology - Perspective of the young committee of the international society of liquid biopsy. J Liq Biopsy 5:100156, 2024. PMID: 40027940.
4. Saldanha EF, Nicolo E, Venetis K, de Miguel Perez D, Ortega-Franco A, Dispasquale A, Gouda MA, Singhal S, Adigbli G, Reduzzi C. The role of liquid biopsy as a catalyst for sustained progress in precision oncology – Perspective of the young committee of the international society of liquid biopsy. The Journal of Liquid Biopsy 5, 2024.
5. Gouda MA, Thein KZ. Selinexor: Changing Paradigm in Patients with TP53 wild-type Endometrial Cancer?. Med 4(11):752-754, 2023. PMID: 37951208.
6. Gouda MA, Subbiah V. Precision oncology for biliary tract tumors: it's written in blood!. Ann Oncol 33(12):1209-1211, 2022. PMID: 36182024.
7. Gouda MA, Subbiah V. Exportin(g) precision oncology beyond genomics with XPO1 inhibition. Med 3(11), 2022. PMID: 36370692.

Abstracts

1. Gouda MA, Xavier CB, Torrado C, Shah PA, Rai K, Vokes N, Alhalabi O, Bedford MT, Gao J, Majd NK, Li J, Javle M, Meric-Bernstam F, Rodon J. Pan-Cancer Prevalence of unusual MTAP Alterations: Data from the AACR GENIE Database. 2025 AACR Annual Meeting.

Book Chapters

1. Gouda MA, Subbiah V. Tissue-Agnostic Cancer Therapy Approvals. In: Precision Oncology and Cancer Surgery. Surgical Oncology Clinics of North America, 2024.

Letters to the Editor

1. Gouda MA. Radiotherapy for Metastatic Prostate Cancer. Lancet 394: 829, 2019.
2. Aboshady OA, Gouda MA. Student research in Arab world. What is the current state?. Saudi Med J 37, 2016.
3. Aboshady OA, Gouda MA. Pros and cons of student journals. Perspect Med Educ 5, 2016.
4. Gouda MA. Common Pitfalls in Reporting the Use of SPSS Software. Med Princ Pract 24: 300, 2015.